{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:57:34Z","timestamp":1793228254880,"version":"4.5.0"},"reference-count":20,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2023,3,7]]},"abstract":"\n Importance<\/jats:title>\n Olamkicept, a soluble gp130-Fc-fusion-protein, selectively inhibits interleukin 6 (IL-6) trans-signaling by binding the soluble IL-6 receptor\/IL-6 complex. It has anti-inflammatory activities in inflammatory murine models without immune suppression.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To assess the effect of olamkicept as induction therapy in patients with active ulcerative colitis.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n Randomized, double-blind, placebo-controlled phase 2 trial of olamkicept in 91 adults with active ulcerative colitis (full Mayo score \u22655, rectal bleeding score \u22651, endoscopy score \u22652) and an inadequate response to conventional therapy. The study was conducted at 22 clinical study sites in East Asia. Patients were recruited beginning in February 2018. Final follow-up occurred in December 2020.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Eligible patients were randomized 1:1:1 to receive a biweekly intravenous infusion of olamkicept 600 mg (n\u2009=\u200930) or 300 mg (n\u2009=\u200931) or placebo (n\u2009=\u200930) for 12 weeks.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary end point was clinical response at week 12 (defined as \u22653 and \u226530% decrease from baseline total Mayo score; range, 0-12 [worst] with \u22651 decrease and \u22641 in rectal bleeding [range, 0-3 {worst}]). There were 25 secondary efficacy outcomes, including clinical remission and mucosal healing at week 12.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Ninety-one patients (mean age, 41 years; 25 women [27.5%]) were randomized; 79 (86.8%) completed the trial. At week 12, more patients receiving olamkicept 600 mg (17\/29 [58.6%]) or 300 mg (13\/30 [43.3%]) achieved clinical response than placebo (10\/29 [34.5%]), with adjusted difference vs placebo of 26.6% (90% CI, 6.2% to 47.1%;\n P<\/jats:italic>\n \u2009=\u2009.03) for 600 mg and 8.3% (90% CI, \u221212.6% to 29.1%;\n P<\/jats:italic>\n \u2009=\u2009.52) for 300 mg. Among patients randomized to receive 600 mg olamkicept, 16 of 25 secondary outcomes were statistically significant compared with placebo. Among patients randomized to receive 300 mg, 6 of 25 secondary outcomes were statistically significant compared with placebo. Treatment-related adverse events occurred in 53.3% (16\/30) of patients receiving 600 mg olamkicept, 58.1% (18\/31) receiving 300 mg olamkicept, and 50% (15\/30) receiving placebo. The most common drug-related adverse events were bilirubin presence in the urine, hyperuricemia, and increased aspartate aminotransferase levels, and all were more common in the olamkicept groups compared with placebo.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n Among patients with active ulcerative colitis, biweekly infusion of olamkicept 600 mg, but not 300 mg, resulted in a greater likelihood of clinical response at 12 weeks compared with placebo. Further research is needed for replication and to assess longer-term efficacy and safety.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT03235752<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jama.2023.1084","type":"journal-article","created":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T11:31:51Z","timestamp":1678188711000},"page":"725","source":"Crossref","is-referenced-by-count":104,"title":["Effect of Induction Therapy With Olamkicept vs Placebo on Clinical Response in Patients With Active Ulcerative Colitis"],"prefix":"10.1001","volume":"329","author":[{"given":"Shenghong","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baili","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bangmao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, General Hospital, Tianjin Medical University, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Affiliated ZhongDa Hospital, School of Medicine Southeast University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Shengjing Hospital of China Medical University, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Jium","family":"Shieh","sequence":"additional","affiliation":[{"name":"Department of Oncology, National Taiwan University Hospital & College of Medicine, Taipei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihua","family":"Ran","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongyu","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Bethune First Affiliated Hospital of Jilin University, Changchun, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Yang","sequence":"additional","affiliation":[{"name":"I-Mab Biopharma (Shanghai), Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beibei","family":"Xu","sequence":"additional","affiliation":[{"name":"I-Mab Biopharma (Shanghai), Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Wang","sequence":"additional","affiliation":[{"name":"I-Mab Biopharma (Shanghai), Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunjie","family":"Liu","sequence":"additional","affiliation":[{"name":"I-Mab Biopharma (Shanghai), Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijia","family":"Ma","sequence":"additional","affiliation":[{"name":"I-Mab Biopharma (Shanghai), Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Wang","sequence":"additional","affiliation":[{"name":"I-Mab Biopharma (Hangzhou), Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Zhang","sequence":"additional","affiliation":[{"name":"I-Mab Biopharma (Hangzhou), Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su","family":"Zhang","sequence":"additional","affiliation":[{"name":"I-Mab Biopharma (Hangzhou), Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyu","family":"Guo","sequence":"additional","affiliation":[{"name":"I-Mab Biopharma (Hangzhou), Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Huang","sequence":"additional","affiliation":[{"name":"I-Mab Biopharma (Hangzhou), Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Schreiber","sequence":"additional","affiliation":[{"name":"Department of Medicine I, University Hospital Schleswig Holstein, Kiel University, Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minhu","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10114","key":"joi230013r1","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies.","volume":"390","author":"Ng","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"joi230013r2","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1053\/j.gastro.2013.04.007","article-title":"Incidence and phenotype of inflammatory bowel disease based on results from the Asia-Pacific Crohn\u2019s and Colitis Epidemiology Study.","volume":"145","author":"Ng","year":"2013","journal-title":"Gastroenterology"},{"issue":"8","key":"joi230013r3","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1111\/jgh.2012.27.issue-8","article-title":"Inflammatory bowel disease in Asia: a systematic review.","volume":"27","author":"Prideaux","year":"2012","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"joi230013r4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2468-1253(19)30333-4","article-title":"The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.","volume":"5","author":"GBD 2017 Inflammatory Bowel Disease Collaborators","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"joi230013r5","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/s12876-021-01745-1","article-title":"The emerging epidemic of inflammatory bowel disease in Asia and Iran by 2035: a modeling study.","volume":"21","author":"Olfatifar","year":"2021","journal-title":"BMC Gastroenterol"},{"issue":"7","key":"joi230013r6","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/S2468-1253(21)00065-0","article-title":"Breaking the therapeutic ceiling in drug development in ulcerative colitis.","volume":"6","author":"Alsoud","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"7","key":"joi230013r7","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1053\/j.gastro.2021.02.062","article-title":"Therapeutic interleukin-6 trans-signaling inhibition by olamkicept (sgp130fc) in patients with active inflammatory bowel disease.","volume":"160","author":"Schreiber","year":"2021","journal-title":"Gastroenterology"},{"issue":"10","key":"joi230013r8","doi-asserted-by":"publisher","first-page":"4958","DOI":"10.4049\/jimmunol.152.10.4958","article-title":"The soluble human IL-6 receptor: mutational characterization of the proteolytic cleavage site.","volume":"152","author":"M\u00fcllberg","year":"1994","journal-title":"J Immunol"},{"issue":"2","key":"joi230013r9","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1002\/(ISSN)1521-4141","article-title":"The soluble interleukin-6 receptor is generated by shedding.","volume":"23","author":"M\u00fcllberg","year":"1993","journal-title":"Eur J Immunol"},{"issue":"2","key":"joi230013r10","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1517\/14728222.2012.660307","article-title":"Hitting a complex target: an update on interleukin-6 trans-signalling.","volume":"16","author":"Waetzig","year":"2012","journal-title":"Expert Opin Ther Targets"},{"issue":"5","key":"joi230013r11","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2020.115327","article-title":"A panoramic review of IL-6: structure, pathophysiological roles and inhibitors.","volume":"28","author":"Kaur","year":"2020","journal-title":"Bioorg Med Chem"},{"issue":"3","key":"joi230013r12","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1074\/jbc.M109.075952","article-title":"N-linked glycosylation is essential for the stability but not the signaling function of the interleukin-6 signal transducer glycoprotein 130.","volume":"285","author":"Waetzig","year":"2010","journal-title":"J Biol Chem"},{"issue":"40","key":"joi230013r13","doi-asserted-by":"publisher","first-page":"27200","DOI":"10.1074\/jbc.M803694200","article-title":"Structure-guided optimization of the interleukin-6 trans-signaling antagonist sgp130.","volume":"283","author":"Tenhumberg","year":"2008","journal-title":"J Biol Chem"},{"issue":"20","key":"joi230013r14","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"23","key":"joi230013r15","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis.","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"issue":"8","key":"joi230013r16","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis.","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"issue":"7","key":"joi230013r17","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1056\/NEJMoa1112168","article-title":"Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.","volume":"367","author":"Sandborn","year":"2012","journal-title":"N Engl J Med"},{"issue":"18","key":"joi230013r18","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis.","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"joi230013r19","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/75068","article-title":"Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo.","volume":"6","author":"Atreya","year":"2000","journal-title":"Nat Med"},{"issue":"6","key":"joi230013r20","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/S2213-2600(21)00103-X","article-title":"Interleukin-6: obstacles to targeting a complex cytokine in critical illness.","volume":"9","author":"McElvaney","year":"2021","journal-title":"Lancet Respir Med"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2802060\/jama_zhang_2023_oi_230013_1677717761.39761.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T11:31:53Z","timestamp":1678188713000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2802060"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2023,3,7]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,3,7]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2023.1084","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3,7]]}}}